6 research outputs found
Efficacy of residual site radiation therapy (ISRT) in patients with primary mediastinal lymphoma with Deauville Score 4 following R-CHT: results of a retrospective mono institutional study
Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in
terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal
lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment
(R-ICHT). Methods: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT,
patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and
were treated with adjuvant RSRT. The chosen techniques for RT delivery were intensity-modulated
radiation therapy (IMRT) or three-dimensional conformal RT (3D-CRT). Most patients underwent
the first one using cone-beam computed tomography (CBCT). All patients were evaluated every
3 months for the first 2 years and every 6 months afterwards for a period of at least 5 years, with
clinical and radiological procedures as required. Results: All patients received RSRT with a dose of
30 Gy in 15 fractions. The median follow-up time of 52.7 months (IQR: 26–64.1 months). The 5-year
OS rate was 100%. The 2-year and 5-year PFS rates were 96.7% and 92.5%, respectively. Patients with
relapsed disease had been treated with high-dose chemotherapy (HDC) and autologous stem cell
transplantation (auto-SCT). Conclusion: RSRT in patients with PMBCL treated with ICHT and DS 4
did not impact unfavorably on patient survival
La [18F]-fluorocolina PET/TC nel carcinoma della prostata: ruolo in fase di stadiazione nella definizione dei protocolli radioterapici dose-escalation nei pazienti ad alto rischio
In Vivo Evaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis
Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncaseating granulomas involving intrathoracic lymph nodes and lung parenchyma. Recently, the use of anti-tumor necrosis factor alpha (anti-TNFα) agents has been introduced for therapy of chronic and refractory sarcoidosis with controversial results. Infliximab (Remicade) is a chimeric monoclonal antibody (mAb) that recognizes and binds TNFα, neutralizing its biological effects. In the present study, Tc 99m labelled infliximab was used to study the expression of TNFα in sarcoid lesions and to evaluate its role as a predictive marker in response to therapy with Remicade. Material and Methods. A total of 10 patients with newly diagnosed sarcoidosis were enrolled together with 10 control patients affected by rheumatoid arthritis. All patients were studied by planar imaging of the chest with Tc 99m-infliximab at 6 h and 24 h and total body [18F]-FDG PET/CT. Regions of interest were drawn over the lungs and the right arm and target-to-background ratios were analysed for Tc 99m-infliximab. SUVmean and SUVmax were calculated over lungs for FDG. Results and Discussion. Image analysis showed low correlation between T/B ratios and BAL results in patients despite positivity at [18F]-FDG PET. Conclusion. In conclusion, patients with newly diagnosed pulmonary sarcoidosis, with FDG-PET and BAL positivity, showed a negative Tc 99m-infliximab scintigraphy
The role of nuclear medicine imaging in inflammatory diseases: drug targets and clinical applications.
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. <i>J. Clin. Med.</i> 2022, <i>11</i>, 7162
In the original publication [...
Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma
The upfront treatment of very elderly and frail patients with diffuse large B-cell lymphoma (DLBCL) is still a matter of debate. Herein, we report results of the metronomic all-oral DEVEC [prednisolone/deltacortene®, vinorelbine (VNR), etoposide (ETO), cyclophosphamide] combined with i.v. rituximab (R). This schedule was administered as a first line therapy in 22 elderly/frail DLBCL subjects (median age = 84.5 years). In 17/22 (77%) patients, the Elderly-IPI-score was high. After a median follow-up of 24 months, 15 patients had died: seven (50%) for causes unrelated to DLBCL or its treatment, six (40%) for progression, and two (13%) for multiorgan failure. Six treatment-pertinent serious-adverse-events occurred. At the end of induction, 14/22 (64%) achieved complete remission; overall survival and event-free survival at 24 months were both 54% (95% CI = 32–72%), while the time to progression was 74% (95% CI = 48–88%). Furthermore, antiproliferative and proapoptotic assays were performed on DLBCL/OCI-LY3 cell-line using metronomic VNR and ETO and their combination. Both metronomic VNR and ETO had concentration-dependent antiproliferative (IC50 = 0.036 ± 0.01 nM and 7.9 ± 3.6 nM, respectively), and proapoptotic activities in DLBCL cells. Co-administration of the two drugs showed a strong synergism (combination index 1) against cell proliferation and survival. This low-dose schedule seems to compare favourably with intravenous-CHEMO protocols used in the same subset. Indeed, the high synergism shown by metronomic VRN+ETO in in vitro studies, explains the remarkable clinical responses and it allows significant dose reductions